Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,479.00-0.33%ETH$2,696.08-0.57%GOLD$4,193.40+0.15%OIL$90.00+0.63%
Smart Investors Daily
SID Premium
BioVie Inc. logo

NASDAQ · BIVI

BioVie Inc.

Healthcare · Biotechnology

$1.44

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 12:15 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.46M
P/E ratio
-0.43
Dividend yield
0.00%
52-week range
$0.82 – $3.79
Volume
135.12K
Avg. volume
141.08K

Price performance · BIVI

BIVI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

BIVI closed at $1.44 after 20 trading sessions, down 30.43% for the selected period.

Last close
$1.44
Period change
-30.43%
Period low
$1.44
Period high
$2.07
Daily close
View OHLC price history
BIVI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.43$1.48$1.42$1.44135.12K
Oct 2, 2026$1.47$1.52$1.46$1.46189.85K
Oct 1, 2026$1.53$1.535$1.46$1.47266.17K
Sep 30, 2026$1.57$1.58$1.50$1.52201.34K
Sep 29, 2026$1.55$1.61$1.52$1.54146.52K
Sep 28, 2026$1.57$1.60$1.53$1.54182.62K
Sep 25, 2026$1.66$1.75$1.58$1.605458.95K
Sep 24, 2026$1.60$1.645$1.595$1.61235.84K
Sep 23, 2026$1.63$1.66$1.59$1.63216.46K
Sep 22, 2026$1.65$1.71$1.61$1.63201.66K
Sep 21, 2026$1.64$1.7599$1.62$1.63411.52K
Sep 18, 2026$1.78$1.84$1.61$1.61406.8K
Sep 17, 2026$1.82$1.8413$1.75$1.78478.85K
Sep 16, 2026$1.76$1.825$1.685$1.72439.98K
Sep 15, 2026$1.90$1.9075$1.565$1.751.15M
Sep 14, 2026$1.90$2.12$1.88$2.05630.14K
Sep 11, 2026$1.92$2.02$1.91$1.93170.76K
Sep 10, 2026$1.95$1.99$1.89$1.91261.85K
Sep 9, 2026$2.04$2.12$1.90$1.97351.37K
Sep 8, 2026$2.055$2.20$2.00$2.07320.03K

Latest BIVI news

The latest Smart Investors Daily articles mentioning BIVI.

Stock researchCompany · Overview

BIVI research

Overview

Company profile and research snapshot.

Company profile

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BIVI recent ratings
DateFirmRatingTarget
Jul 1, 2024ThinkEquityBuy—
Nov 30, 2023OppenheimerOutperform—
Aug 22, 2023Cantor FitzgeraldOverweight—
Jul 18, 2023Cantor FitzgeraldOverweight—
May 17, 2023Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 26, 2026

New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global

Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p. ET broadcast reaching audiences across the United States, Latin America and MENANEW YORK CITY, NY / ACCESS Newswire / September 26, 2026 / , the financial-media platform for public companies, pre-IPO companies and entrepreneurs, today announced that Show 773 will air tonight at 6:30 p.

Yahoo · Sep 16, 2026

Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could strengthen the case for targeting inflammation and insulin resistance across neurological disordersORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar on September 23, 2026, at 11:00 a.The exclusive event will feature BioVie President and CEO Cuong Do

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By